TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17301566
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA > 600 IU/ml at week 4
Study: 11585082
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg every 8 h)
Study: 9827406
Drug: D-Dimer test
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Dimer test with a cutoff value below 2 micrograms/ml
Study: 9827406
Drug: D-Dimer test
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Dimer test with a cutoff value over 4 micrograms/ml
Study: 28511647
Drug: Traditional cookstove
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional cookstove (chulha) or a combination of traditional stove and kerosene/diesel stove
Study: 24303810
Drug: Traditional Behavioral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Behavioral Couples Therapy (TBCT)
Study: 24303810
Drug: Integrative Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative Behavioral Couples Therapy (IBCT)
Study: 12553852
Drug: alefacept (0.025,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alefacept (0.025, 0.075, or 0.150 mg/kg)
Study: 10674226
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (daily distribution of two oral supplements, each containing 200 kcal for 15 days)
Study: 8369008
Drug: Vitex agnus
Normalized name: VITEX AGNUS-CASTUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitex agnus castus preparation (20 mg daily)
Study: 2878676
Drug: Oral xamoterol
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral xamoterol (200 mg twice daily)
Study: 10367991
Drug: I2‐imidazoline receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: I2‐imidazoline receptor density in ATD patients (8.4 and 14.3 fmol/mg protein)
Study: 10367991
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between I2‐imidazoline receptors and MAO‐B activity
Study: 7884434
Drug: Amonafide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amonafide (300 mg/m2 daily for 5 days)
Study: 21849147
Drug: Hirudoid cream
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudoid cream
Study: 7458751
Drug: Various chemical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various chemical agents administered to influence microcirculation and metabolism of the inner ear.
Study: 7458751
Drug: NaCl infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl infusions and glucose tablets (control group).
Study: 7458751
Drug: Polypragmatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypragmatic therapy (four different forms).
Study: 31642928
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy for 16 weeks
Study: 31642928
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavior therapy for 16 weeks
Study: 24440324
Drug: Evidence-based medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medications at discharge in high-income countries
Study: 22523593
Drug: 1,2-octanediol lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,2-octanediol lotion (20% alcohol) applied for 2-2.5 hours
Study: 22523593
Drug: 1,2-octanediol lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,2-octanediol lotion (20% alcohol) applied for 8 hours/overnight
Study: 20673378
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet + placebo capsules
Study: 20673378
Drug: 40 mmol
Normalized name: citrate 18 mmol / sodium 140 mmol in L Injection (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mmol potassium citrate capsules/d
Study: 16115933
Drug: Doxil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil (40 mg/m2 i.v. on day 1) and continuous infusion topotecan (0.4 mg/m2/day for 14 days)
Study: 16115933
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (0.4 mg/m2 bid for 14 days)
Study: 16115933
Drug: Doxil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil with 14‐day topotecan infusion
Study: 16115933
Drug: Doxil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxil and continuous infusion topotecan
Study: 10200009
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy (cat/dust mite)
Study: 10200009
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (active immunotherapy and placebo)
Study: 6796106
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral cyclophosphamide (arm S)
Study: 6796106
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral cyclophosphamide, hexamethylmelamine and methotrexate on a pulsed basis (arm T)
Study: 27124881
Drug: Dexamethasone delayed
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone delayed delivery system monotherapy
Study: 24535625
Drug: Luseogliflozin (1-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (1-25 mg single dose)
Study: 24535625
Drug: Luseogliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (5 or 10 mg/day for 7 days)
Study: 20862940
Drug: Shallow needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow needling combined with acupoint application on top of routine medication.
Study: 20862940
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (control group).
Study: 19049703
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg twice daily + bicarbonate hydration
Study: 9364366
Drug: Intermittent testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent testosterone enanthate treatment (25‐100 mg every two weeks for three months)
Study: 3971528
Drug: Control (drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (drug-free state)
Study: 29516990
Drug: Thalidomide 150
Normalized name: thalidomide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 150 mg/day and cinobufagin 2700 mg/day
Study: 29516990
Drug: Cinobufagin 2700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinobufagin 2700 mg/day (Control)
Study: 26849844
Drug: SEP-432 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-432 (300 mg/day)
Study: 25391194
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid for 2 months
Study: 18455727
Drug: Active pill
Normalized name: Factive Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pill phase (oral contraceptives)
Study: 15932917
Drug: PCOS patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOS patients without metformin therapy
Study: 12940609
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg) and dipyridamole (5 mg/kg) for 1 year
Study: 12940609
Drug: Dipyridamole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (5 mg/kg) only for 1 year
Study: 1763597
Drug: Heparin injection
Normalized name: heparin Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin injection
Study: 30169462
Drug: Valaciclovir 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 8 g daily
Study: 15936423
Drug: Corticosteroids (methylprednisolone)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone) administered via a 48-hour infusion
Study: 1718250
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (argon green or krypton red lasers)
Study: 20572378
Drug: Generic product
Normalized name: Generlac Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic product of a single oral 8 mg rosiglitazone tablet
Study: 20572378
Drug: Innovator's product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator's product of a single oral 8 mg rosiglitazone tablet
Study: 12682308
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg per os twice a day)
Study: 11110418
Drug: Herpes simplex
Normalized name: herpes simplex 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy by direct intracerebral injection of retrovirus (RV) vector producing cells (VPC) during tumor surgery and subsequent systemic administration of GCV
Study: 11110418
Drug: Herpes simplex
Normalized name: herpes simplex 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy
Study: 11110418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving HSV‐tk/GCV gene therapy)
Study: 1922908
Drug: Frusemide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 0.5 mg/kg body weight (Study 1)
Study: 1922908
Drug: Frusemide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 1.0 mg/kg body weight (Study 2)
Study: 29615172
Drug: Trabeculectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trabeculectomy without adjunctive mitomycin C
Study: 22823552
Drug: Pharmacist-delivered medication
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-delivered medication therapy management (MTM) intervention
Study: 18544146
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.03 mcg.kg(‐1).min(‐1)
Study: 7834970
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (100% humidified at 101/min for 8-10 h prior to ultrasound)
Study: 1972836
Drug: EMLA 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 2% cream
Study: 25075
Drug: Oxprenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (100 mg)
Study: 31523169
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao (YB) treatment
Study: 27990643
Drug: CN-105 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN-105 (active treatment)
Study: 26030115
Drug: Nonhorticultural occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhorticultural occupational therapy (OT)
Study: 31220560
Drug: Bushen capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen capsules (BSC)
Study: 25503617
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU) administered twice daily for 1 week
Study: 25503617
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (48 IU) administered twice daily for 1 week
Study: 25503617
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (72 IU) administered twice daily for 1 week
Study: 19351734
Drug: Arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 20 mg/d
Study: 1756116
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of UVA (80‐160 J/cm2; 340‐440 nm) after treatment
Study: 6187065
Drug: Disopyramide retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide retard (DR) 2 X 300 mg/day
Study: 6187065
Drug: Propranolol retard
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Avlocardyl Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol retard (PR) 1 X 160 mg/day
Study: 31606753
Drug: D-fortified sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fortified sunflower oil (500 IU/30 g)
Study: 27575992
Drug: HB-C (home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-C (home-based computer vergence/accommodative therapy)
Study: 27575992
Drug: HB-PU (home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-PU (home-based near target push-up therapy)
Study: 27575992
Drug: HB-P (home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-P (home-based placebo treatment)
Study: 18315940
Drug: Intramuscular IFNbeta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular IFNbeta‐1a (Avonex) 30 microg once weekly
Study: 18315940
Drug: Subcutaneous IFNbeta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFNbeta‐1a (Rebif) 44 microg three times per week
Study: 19444734
Drug: Behavioral Naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Naltrexone Therapy
Study: 19444734
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral therapy
Study: 10726104
Drug: 1.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/day of LC n‐3 PUFA
Study: 8530611
Drug: Potassium bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium bicarbonate (KHCO3, 2 meq/kg/day in divided doses)
Study: 25422026
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy combined with physical training
Study: 22495117
Drug: 1.9 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 µg HA + AS03B (5.93 mg α‐tocopherol) vaccine (6 mo‐9 y)
Study: 22495117
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg HA + AS03A (11.86 mg α‐tocopherol) vaccine (10‐17 y)
Study: 15658946
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise and manipulative therapy
Study: 7906279
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg SDZ CO 611
Study: 7906279
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg SDZ CO 611
Study: 7906279
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day SDZ CO 611
Study: 236209
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N NaHCO3 (alkaline solution)
Study: 31408377
Drug: Antidiabetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic treatment with glyburide, metformin, or pioglitazone
Study: 25487313
Drug: OSAS patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSAS patients before CPAP treatment
Study: 24056618
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction followed by tacrolimus monotherapy
Study: 21401538
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg + Ondansetron 4 mg
Study: 19921359
Drug: Group B+Mor+Mg
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B+Mor+Mg (20 ml 0.25% bupivacaine, morphine 2 mg, magnesium 150 mg)
Study: 19921359
Drug: Group B+Mor
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B+Mor (20 ml 0.25% bupivacaine, morphine 2 mg)
Study: 19921359
Drug: Group B+Mg
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B+Mg (20 ml 0.25% bupivacaine, magnesium 150 mg)
Study: 19921359
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (20 ml 0.25% bupivacaine)
Study: 10992996
Drug: Pharmacological lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological lipid therapy
Study: 10992996
Drug: Standard lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lipid therapy in secondary prevention
Study: 10992996
Drug: Primary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary prevention lipid therapy
Study: 9347245
Drug: Troglitazone (TR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (TR), 200 mg once daily
Study: 8185689
Drug: Minocycline (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (maximal oral daily dose 200 mg)
Study: 29377462
Drug: selonsertib (SEL)
Normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: selonsertib (SEL) 6 mg or 18 mg orally QD
Study: 28826616
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg/day for 3 months, then escalated to 15 mg/day)
Study: 21585060
Drug: Medication (Rupixiao)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Rupixiao)
Study: 19364999
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity advice and prescription by physicians (intervention group)
Study: 16937497
Drug: Empirical prokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical prokinetic treatment with cisapride
Study: 28002709
Drug: Amoxicillin‐clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate for 5 days
Study: 28002709
Drug: Amoxicillin‐clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate for 10 days
Study: 18691579
Drug: Endoluminal image
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoluminal image analysis using capsule technology (Pillcam)
Study: 11029132
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel hand sanitizer used by students and staff when entering and leaving the classroom.
Study: 11029132
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alcohol gel hand sanitizer used).
Study: 11029132
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel hand sanitizer used in schools with the largest teacher population (n = 246).
Study: 8640699
Drug: Fadrozole HCL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole HCL, 1 mg twice daily
Study: 8640699
Drug: Megestrol acetate,
Normalized name: megestrol acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol acetate, 40 mg 4 times daily
Study: 3535990
Drug: One year's
Approvals — FDA: no, EMA: no, PMDA: no
Description: One year's adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil
Study: 29670330
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (120 mg/day)
Study: 12817758
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily for 3 years
Study: 8866927
Drug: CFC-free metered-dose
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC-free metered-dose inhaler (CFC-free)
Study: 8866927
Drug: CFC metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC metered-dose inhaler (CFC)
Study: 1801963
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine maleate (50 mg, tablet) after overnight fast
Study: 1801963
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine maleate (50 mg, tablet) after breakfast
Study: 6144244
Drug: Relaxation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation Therapy (R)
Study: 6144244
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy of Dynamic Type (ST)
Study: 6144244
Drug: Basal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Therapy (B)
Study: 26762838
Drug: Anti-TNF agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF agents (anti-TNF group)
Study: 25384473
Drug: Double-spinning platelet-enriched
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-spinning platelet-enriched gel (PRP) with leukocytes
Study: 25384473
Drug: Single-spinning platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-spinning platelet-rich preparation (PRGF Endoret® Technology) without leukocytes
Study: 25384473
Drug: Non-gel group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gel group (control)
Study: 16193341
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g L-carnitine
Study: 10434221
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate (12.5 mg, 25 mg, 50 mg, or 100 mg)
Study: 7599221
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg daily for three months)
Study: 2189951
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg daily) for 2 or 5 years
Study: 708560
Drug: Three formulations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three formulations of etomidate